An assortment of recent news releases highlights the highs and lows in Biogen Inc.'s journey. Biogen (NASDAQ:BIIB) has announced the FDA's acceptance of their sBLA for Leqembi in partnership with Eisai. The Q2 earnings surpassing estimates and shares going up, alongside EU approval for rare disease Drug Qalsody, and steps taken to buy HI-Bio to expand the rare disease pipeline, and positive Q1 results despite lower revenues further demonstrate the company's strong positioning. However, Biogen has faced several legal struggles with various entities encouraging shareholders to participate in class action suits regarding securities fraud. Struggles also persist with product launches and developments, with the company recently discontinuing the development of an ALS drug, and stock falling amidst market uptick. Moreover, doubts about the future have surfaced, causing some fluctuations in stock prices. Nevertheless, unexpected boosts, like FDA delaying decisions on rival products and strong momentum, have helped the company.
Biogen BIIB News Analytics from Fri, 28 Jul 2023 07:00:00 GMT to Sun, 23 Jun 2024 17:11:14 GMT - Rating 2 - Innovation 5 - Information 3 - Rumor -8
